Snus usage: Harm induction or harm reduction?

Abstract

Get full access to this article

View all access options for this article.

References

Rodu

Jansson

J-H

Eliasson

. The low prevalence of smoking in the Northern Sweden MONICA study, 2009. Scand J Publ Health 2013;41:808–11.

Peeters

Gilmore

. Transnational tobacco company interests in smokeless tobacco in europe: analysis of internal industry documents and contemporary industry materials. PLoS Med 2013;10:e1001506.

Luo

Zendehdel

. Oral use of Swedish moist snuff (snus) and risk for cancer of the mouth, lung, and pancreas in male construction workers: a retrospective cohort study. The Lancet 2007;369:2015–20.

Arefalk

Hergens

M-P

Ingelsson

. Smokeless tobacco (snus) and risk of heart failure: results from two Swedish cohorts. Eur J Prev Cardiol 2012;19:1120–7.

Östenson

C-G

Hilding

Grill

. High consumption of smokeless tobacco (“snus”) predicts increased risk of type 2 diabetes in a 10-year prospective study of middle-aged Swedish men. Scand J Publ Health 2012;40:730–7.

Mejia

Ling

Glantz

. Quantifying the effects of promoting smokeless tobacco as a harm reduction strategy in the USA. Tob Control 2010;19:297–305.

Hamari

Toljamo

Kinnula

. Dual use of cigarettes and Swedish snuff (snus) among young adults in Northern Finland. Eur J Publ Health 2013;23:768–71.